- Partnerships Remain Crucial to Future Development – By David Y. Mitchell Oct 2, 2012 Pharmaceutical Technology Volume 36, Issue 10, pp. 14
- Application of a single-objective, hybrid genetic algorithm approach to pharmacokinetic model building – J Pharmacokinet Pharmacodyn (2012) 39:393–414 – Mark Sale, MD – Vice President, Modeling & Simulation and Executive Consultant, Population PK.
- Example of PK/PD analyses on an anticoagulation compound conducted by Bill Wargin, PhD (CSO) – Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and pharmacodynamic substudy. Povsic TJ, Wargin WA, Alexander JH, Krasnow J, Krolick M, Cohen MG, Mehran R, Buller CE, Bode C, Zelenkofske SL, Rusconi CP, Becker RC; RADAR Investigators. Eur Heart J. 2011 Oct;32(19):2412-9.
- White Paper – Advising organisations on optimising clinical pharmacology studies to produce robust pharmacokinetic and pharmacodynamic (PK, PD) data sets. No one sets out to conduct a clinical study that will not meet its objectives. However, all too often, studies fail to meet their objectives. PDF